FDA Study Of Botox Safety Deepens Allergan's Frown

Law360, New York (February 8, 2008, 12:00 AM EST) -- Still smarting from recent public scrutiny from a consumer advocacy group over Botox, Allergan Inc. has been hit with more bad news. The U.S. Food and Drug Administration announced Friday it will conduct a safety review of the popular cosmetic treatment and a similar product, Myobloc, after receiving reports of deaths and breathing problems in some patients.

Allergan's Botox and Solstice Neurosciences Inc.'s Myobloc have been linked in some cases to adverse reactions, including respiratory failure and death, following treatment of a variety of conditions using...
To view the full article, register now.